Skip to main content

Table 3 Comparison of serum testing indexes expression changes in CHB patients with different pathological changes of liver tissue

From: Expression changes of Tim-3 as one of supplementary indicators for monitoring prognosis of liver pathological changes in chronic HBV infection

Index

Stable condition(n = 46)

Clinical remission (n = 74)

Clinical disease progression (n = 65)

Baseline level

(95%CI)

One year later

(95%CI)

Baseline level

(95%CI)

One year later

(95%CI)

Baseline level

(95%CI)

One year later

(95%CI)

ALT, U/L

41.17 ± 65.88

(21.61–60.74)

25.26 ± 21.11#

(18.99–31.53)

66.55 ± 93.83

(44.82–88.29)

21.58 ± 13.66##

(18.42–24.75)

39.52 ± 55.32

(25.81–53.23)

29.61 ± 35.81

(20.24–38.49)

AST, U/L

39.09 ± 51.56

(23.77–54.40)

25.96 ± 18.01##

(20.61–31.30)

60.23 ± 83.49

(40.89–79.57)

23.96 ± 8.92##

(21.89–26.03)

39.05 ± 48.70

(26.98–51.11)

29.06 ± 16.79

(24.90–33.22)

γ-GT, U/L

33.72 ± 33.50

(23.77–43.67)

23.07 ± 14.57

(18.74–27.39)

50.62 ± 51.74

(38.63–62.61)

26.57 ± 27.40##

(20.22–32.92)

36.69 ± 31.62

(28.86–44.53)

30.58 ± 28.16

(23.61–37.56)

Tim3, pg/mL

800.93 ± 520.55

(646.34–955.51)

712.20 ± 428.81

(584.86–839.54)

991.41 ± 792.25

(807.86–1174.96)

644.67 ± 431.30##

(544.74–744.59)

806.94 ± 519.25

(678.28–935.60)

629.07 ± 337.39#

(545.47–712.67)

Inflammation Grade

1.30 ± 0.47

(1.17–1.44)

1.28 ± 0.46

(1.15–1.42)

2.15 ± 0.69

(1.99–2.31)

1.22 ± 0.48##

(1.11–1.33)

1.22 ± 0.60

(1.07–1.36)

1.63 ± 0.601#

(1.48–1.78)

Fibrosis Stage

1.24 ± 0.90

(0.97–1.51)

1.20 ± 0.86

(0.94–1.45)

1.97 ± 1.01

(1.74–2.21)

1.05 ± 0.98##

(0.83–1.28)

0.62 ± 0.74

(0.43–0.80)

1.77 ± 0.825#

(1.56–1.97)

  1. #P < 0.05 versus the baseline level; ##P < 0.01 versus the baseline level